Targets › TNFSF13B
8 programs from 8 companies in 27 trials: 14 Phase 2, 5 Phase 4, 4 Phase 3, 4 Phase 1; Immunology, Oncology, Genitourinary; next expected readout Jan 2027.
Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. (UniProt, Q9Y275)
Open in Phaseline: the race on TNFSF13B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tongji Hospital | Telitacicept Freeze-dried powder Injection 80mg TACI-Fc fusion protein targeting BLyS and APRIL | TNFSF13B, TNFSF13 | Phase 4 | Lupus or SLE | Mar 2027 |
| GSK | Belimumab Tumor necrosis factor ligand superfamily member 13B inhibitor | TNFSF13B | Phase 4 | Systemic Lupus Erythematosus; Lung Diseases, Interstitial; Connective Tissue Diseases; Systemic Sclerosis Associated Interstitial Lung Disease … | Jun 2027 |
| Vera Therapeutics | Atacicept Tumor necrosis factor ligand superfamily member 13B inhibitor; Tumor necrosis factor ligand superfamily member 13 inhibitor | TNFSF13B, TNFSF13 | Phase 3 | IgA Nephropathy; IgA Nephropathy (IgAN); pMN | Sep 2027 |
| Zura Bio | Tibulizumab (ZB-106) Tumor necrosis factor ligand superfamily member 13B inhibitor; Interleukin 17A inhibitor | TNFSF13B, IL17A | Phase 2 | Hidradenitis Suppurativa (HS); Systemic Sclerosis (SSc) | Apr 2027 |
| Beijing Tongren Hospital | Taitacept (Telitacicept) BAFF receptor fusion protein; inhibitor of B-cell activating factor (BAFF) and a prolifera | TNFSF13B | Phase 2 | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Jul 2027 |
| Xuzhou Medical University | APRIL-BAFF-Bicephali CAR-T cells Dual-targeted CAR-T cell therapy against APRIL and BAFF ligands | TNFSF13, TNFSF13B | Phase 1 | Multiple Myeloma | Jan 2027 |
| Mayo Clinic | Autologous BAFFR-targeting CAR T Cells BAFFR-targeted CAR T cell therapy | TNFSF13B | Phase 1 | B-Cell Non-Hodgkin Lymphoma | Dec 2040 |
| Luminary Therapeutics | LMY-920 BAFF CAR-T cells targeting BAFF ligand | TNFSF13B | Phase 1 | Systemic Lupus Erythematosus | – |
Systemic Lupus Erythematosus (3) Lung Diseases, Interstitial (1) Connective Tissue Diseases (1) Systemic Sclerosis Associated Interstitial Lung Disease (1) Sjogren's Syndrome (1) Lupus Nephritis (1) Lupus Erythematosus, Systemic (1) Primary Immune Thrombocytopenia (ITP) (1) Antiphospholipid Syndrome (APS) (1) Systemic Lupus Erythematosus (SLE) (1) Chronic Lymphoid Leukemia in Relapse (1) Systemic Sclerosis (1)
antibody (4), mixed (2), protein or peptide (1)
GSK (1) Xuzhou Medical University (1) Mayo Clinic (1) Beijing Tongren Hospital (1) Vera Therapeutics (1) Zura Bio (1) Luminary Therapeutics (1) Tongji Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.